Axios

@axios ↗

Deleted No

Hibernated Yes

Last Checked Oct. 26, 2022

Created

Fri Sep 02 18:41:44 +0000 2022

Likes

131

Retweets

Source

Twitter Web App

View Raw Data

JSON Data

View on Twitter

Likely Available

Axios @axios

The prospect of reinfection shouldn't discourage older or high-risk patients from taking the pills, said Yale infectious diseases specialist Scott Roberts. "Rebound is almost always more mild than initial course," Roberts told Axios. https://t.co/fxiAnLSFZh — PolitiTweet.org

Posted Sept. 2, 2022 Hibernated

Preceded By

Axios @axios

A large study of more than 109,000 people in the New England Journal of Medicine concluded the drug significantly reduced hospitalizations and deaths among patients aged 65 and older but that there was no evidence of benefit in younger adults. https://t.co/fxiAnLSFZh — PolitiTweet.org

Posted Sept. 2, 2022 Hibernated

Followed By

Axios @axios

Paxlovid could have the added benefit of warding off long COVID, or symptoms that linger beyond the first 30 days after testing positive, and studies to determine this are underway. https://t.co/fxiAnLSFZh — PolitiTweet.org

Posted Sept. 2, 2022 Hibernated